Vilaprisan (BAY1002670)
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Fibroids and Heavy Menstrual Bleeding
Conditions
Uterine Fibroids and Heavy Menstrual Bleeding
Trial Timeline
Mar 30, 2018 → Jul 12, 2021
NCT ID
NCT03476928About Vilaprisan (BAY1002670)
Vilaprisan (BAY1002670) is a phase 3 stage product being developed by Bayer for Uterine Fibroids and Heavy Menstrual Bleeding. The current trial status is terminated. This product is registered under clinical trial identifier NCT03476928. Target conditions include Uterine Fibroids and Heavy Menstrual Bleeding.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03476928 | Phase 3 | Terminated |
| NCT03411980 | Phase 1 | Completed |
| NCT03240523 | Phase 3 | Terminated |
| NCT03092999 | Phase 1 | Completed |
| NCT02262663 | Phase 1 | Completed |
Competing Products
20 competing products in Uterine Fibroids and Heavy Menstrual Bleeding